Quarterly report pursuant to Section 13 or 15(d)

EQUITY (Details Narrative)

v3.8.0.1
EQUITY (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended
Mar. 03, 2017
May 31, 2018
Mar. 31, 2018
Mar. 27, 2018
Apr. 19, 2017
Mar. 31, 2017
Mar. 31, 2018
Dec. 31, 2017
Preferred stock, authorised     10,000,000       10,000,000 10,000,000
Preferred stock, par value (in dollars per share)     $ 0.0001       $ 0.0001 $ 0.0001
Common stock, authorised     490,000,000       490,000,000 490,000,000
Common stock, par value (in dollars per share)     $ 0.0001       $ 0.0001 $ 0.0001
Preferred stock, issued     0       0 0
Preferred stock, outstanding     0       0 0
Common stock, issued     70,278,622       70,278,622 70,278,622
Common stock, outstanding     69,758,622       69,758,622 70,278,622
Term         1 year      
Refundable deposit             $ 3,000,000  
Accrued and unpaid interest     $ 375,096       375,096 $ 138,110
DOING Biomedical Technology Co., Ltd                
Accrued and unpaid interest     1,000,000       1,000,000  
Related party repayment obligation   $ 200,000 200,000          
Third party                
Common stock repurchased, Shares       520,000        
Common stock repurchased, Value       $ 522,500        
Escrow agent                
Share repurchase cost       $ 2,500        
Accredited investor | Subscription Agreement                
Common stock issued, Shares 3,000,000         3,000,000    
Common stock issued, Value $ 3,000,000         $ 3,000,000    
Accredited investor | Subscription Agreement | Avalon (Shanghai) Healthcare Technology Co., Ltd.                
Annual interest           20.00%    
Principal amount             3,000,000  
Share price           $ 1.20    
Term           3 years    
Employee Stock Option [Member]                
Aggregate fair value of options granted             289,150  
Compensation and related benefits             72,287  
Aggregate value of nonvested options     1,849,616       $ 1,849,616  
Amortization of stock-based compensation expense             1 year 9 months 29 days  
Intrinsic value of stock options outstanding     3,945,700       $ 3,945,700  
Intrinsic value of stock options exercisable     1,568,956       1,568,956  
Non Employee Stock Option [Member]                
Aggregate value of nonvested options     67,398       $ 67,398  
Amortization of stock-based compensation expense             29 days  
Intrinsic value of stock options outstanding     253,800       $ 253,800  
Intrinsic value of stock options exercisable     $ 126,900       $ 126,900